Risk factors
Pulse Biosciences (PLSE) risk factors
Item 1A of every Pulse Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors66 risks2 new2 dropped11 reworded
Competition discussion now centers on nPulse treatment of benign thyroid nodules against surgery and RFA/MWA incumbents.
Filed Feb 19, 2026 - FY2024 10-K risk factors66 risks
Pulse Biosciences relies entirely on its unproven Nano-pulse Stimulation technology and CellFX System for future revenues. The company faces ongoing operating losses, liquidity needs, and rigorous FDA regulatory hurdles for medical devices. Intellectual property protection and specialized talent retention are critical for commercialization.
Filed Mar 31, 2025